Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis

Kitamura, Koji; Hatano, Etsuro; Higashi, Tatsuya; Narita, Michiko; Seo, Satoru; Nakamoto, Yuji; Yamanaka, Kenya; Nagata, Hiromitsu; Taura, Kojiro; Yasuchika, Kentaro; Nitta, Takashi; Üemoto, Shinji

doi:10.1016/j.jhep.2011.01.038

Cited by 119 publications

(118 citation statements)

References 48 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…To enable a high glycolytic capacity, the liver cancer tissue must attain an enhanced uptake of glucose. While glucose transporter 2 is most important in healthy liver, the fetal glucose transporter 1 is upregulated in HCC, and its expression is correlated with HCC proliferation and invasiveness [84][85][86][87]. Moreover, patients with a high glucose transporter 1 expression showed higher α-fetoprotein (HCC tumor marker) and poorer differentiation compared to the glucose transporter 1 low-expression cohort [88].…”

Section: Metabolic Alterations In Liver Cancermentioning

confidence: 99%

Organ-Specific Cancer Metabolism and Its Potential for Therapy

Elia

Schmieder

Christen

et al. 2015

Handbook of Experimental Pharmacology

104

View full text Add to dashboard Cite

KEYWORDS:Cancer metabolism, metabolic therapy, tissue specific metabolism, genetic drivers, epigenetic drivers, microenvironment, Warburg effect, reverse Warburg effect, mixed Warburg effect, triple-negative breast cancer, estrogen receptor positive breast cancer; prostate cancer, liver cancer, gluconeogenesis, fatty acid metabolism, glucose metabolism, glutamine metabolism, serine metabolism, metabolic normalization, metabolic depletion ABSTRACTTargeting the metabolism of cancer cells has the potential to lead to major advances in tumor therapy. Numerous promising metabolic drug targets have been identified. Yet, it has emerged that there is no singular metabolism that defines the oncogenic state of the cell. Rather, the metabolism of cancer cells is a function of the requirements of a tumor. Hence, the tissue of origin, the (epi)genetic drivers, aberrant signaling, and the microenvironment all together define these metabolic requirements. In this chapter we discuss in light of (epi)genetic, signaling, and environmental factors the diversity in cancer metabolism based on triple-negative and estrogen receptor positive breast cancer, early and late stage prostate cancer, and liver cancer. These types of cancer all display distinct and partially opposing metabolic behaviors (e.g. Warburg versus reverse Warburg metabolism). Yet, for each of the cancers their distinct metabolism supports the oncogenic phenotype. Finally, we will assess the therapeutic potential of metabolism based on the concepts of metabolic normalization and metabolic depletion.

show abstract

Section: Metabolic Alterations In Liver Cancermentioning

confidence: 99%

Organ-Specific Cancer Metabolism and Its Potential for Therapy

Elia

Schmieder

Christen

et al. 2015

Handbook of Experimental Pharmacology

104

View full text Add to dashboard Cite

show abstract

“…Background nontumor liver uptake varies to some extent, and the contrast between the liver tumor and background liver noise may depend on the extent of tumor uptake itself as well as on the general liver background [23]. Thus, TNR showed similar or better prognostic value than SUV in PET diagnosis of HCC [18,19,36].…”

Section: Discussionmentioning

confidence: 99%

Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors

Song

Lee

Kim

et al. 2015

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…The glucose metabolism of HCC is related to tumor grade and aggressive biological properties such as differentiation/ microvascular invasion and can be assessed with F-18 FDG-PET (21,22). Therefore, the FDG avidity of HCC seems to be a potential biomarker for pretransplant evaluation of the risk of HCC recurrence after LT.…”

Section: Fluorodeoxyglucose Positron Emission Tomography (Fdg-pet) Scanmentioning

confidence: 99%

Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes

Lin

Chen

2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

Liver transplantation (LT) for hepatocellular carcinoma (HCC) at Kaohsiung Chang GungMemorial Hospital mainly relies on live donor LT (LDLT). Owing to taking the risk of LD, we are obligated to adopt strict selection criteria for HCC patients and optimize the pre-transplant conditions to ensure a high disease-free survival similar to those without HCC, even better than deceased donor LT (DDLT).Better outcomes are attributed to excellent surgical results and optimal patient selection. The hospital mortality of primary and salvage LDLT are lower than 2% in our center. Although Taiwan Health Insurance Policy extended the Milan to University of California, San Francisco (UCSF) criteria in 2006, selection criteria will not be consolidated to take into account only by the morphologic size/number of tumors but also by their biology. The criteria are divided into modifiable image morphology, alpha fetoprotein (AFP), and positron emission tomography (PET) scan with standard uptake value (SUV) and unmodifiable unfavorable pathology such as HCC combined with cholangiocarcinoma (CC), sarcomatoid type, and poor differentiation. Downstaging therapy is necessary for HCC patients beyond criteria to fit all modifiable standards. The upper limit of downstaging treatment seems to be extended by more effective drug eluting transarterial chemoembolization in cases without absolute contraindications. In contrast, the pitfall of unmodifiable tumor pathology should be excluded by the findings of pretransplant core biopsy/resection if possible. More recently, achieving complete tumor necrosis in explanted liver could almost predict no recurrence after transplant. Necrotizing therapy is advised if possible before transplant even the tumor status within criteria to minimize the possibility of tumor recurrence. LDLT with low surgical mortality in experienced centers provides the opportunities of optimizing the pre-transplant tumor conditions and timing of transplant to achieve better outcomes.

show abstract

Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis

Abstract: These data suggest that (1) the proliferative activity of a resected specimen predicted the prognosis in patients with HCC; (2) the proliferative activity was closely correlated with the glucose metabolism, but not with angiogenesis.

Cited by 119 publications

References 48 publications

Organ-Specific Cancer Metabolism and Its Potential for Therapy

Organ-Specific Cancer Metabolism and Its Potential for Therapy

Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors

Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes

Contact Info

Product

Resources

About